MUTYH and breast cancer: A more detailed analysis did note higher response rates for patients with DDR+ breast cancer (55% vs 25% DDR-), BRCA1 mutations (50% vs 23% DDR-), and MUTYH mutations (40% vs 23% DDR-), but none of these subgroups reached statistical significance due to the small sample sizes.